SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MULN symbol is trending due to significant community discussion surrounding a new 'Mullen Army' crypto token that leverages the controversial Mullen Automotive name; many investors are expressing strong skepticism, citing the stock's history of reverse splits and dilution, while some proponents claim the token offers utility and a revolutionary movement.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending driven by institutional interest following a Grayscale S-1 filing for a NEAR Trust, alongside its expanding utility in cross-chain liquidity via 'NEAR Intents' and significant advancements in AI integration. Despite recent price volatility that has divided community sentiment, many are accumulating, banking on its reduced token inflation and strategic position in the AI-crypto ecosystem.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following FDA approval for Bysanti, an antipsychotic granted New Chemical Entity (NCE) status with patent protection until 2044. The community views this unexpected long-term exclusivity as a transformative event, anticipating significant analyst re-ratings and potential multi-billion dollar buyout offers from major pharmaceutical companies seeking to address their own patent cliffs, alongside excitement for Vanda's broader pipeline, including a GLP-1 related nausea drug.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending amid active community discussion regarding its "move-to-earn" utility and speculation on its future valuation. Investors are divided between those accumulating with long-term hopes for a rebound and those cautioning against its volatile nature, often noting its association with NEAR Protocol.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies Group is gaining attention for its rapid deployment of AI-driven Edge Data Centers in underserved markets and its strategic partnership providing mobile power solutions to address burgeoning AI infrastructure demand. The community is actively discussing the company's strong revenue growth, significant backlog, and the perceived undervaluation of its pivotal role in edge computing and power generation for the expanding AI sector.

Frontera Energy Corp. engages in the exploration, development, production, transportation, storage, and sale of oil and natural gas. It operates interests in exploration and production blocks in Colombia, Ecuador and Guyana, and pipeline and port facilities in Colombia. The company was founded on April 10, 1985 and is headquartered in Calgary, Canada.

Frontera Energy Corporation - Ordinary Shares New

Frontera Energy is trending due to the anticipated cash distribution from the sale of its Colombian E&P assets and an ongoing strategic review of its remaining infrastructure business, with investors keenly focused on the vast potential and contentious dispute over its Corentyne block in the highly sought-after Guyana-Suriname Basin.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is seeing a divisive sentiment as its price languishes at multi-year lows following token unlocks and limited initial inflow to its new spot ETF. Despite this, community members are accumulating, pointing to its expanding role in Real-World Asset (RWA) tokenization and anticipated regulatory clarity as strong long-term growth drivers.

BW LPG Ltd. is an investment holding company, which engages in ship owning and chartering. It operates through the Shipping and Product Services segments. The Shipping segment operates spot voyages and time charters. The Product Services segment provides LPG delivery services. The company was founded in 1955 and is headquartered in Singapore.

BW LPG Limited

BWLP is gaining traction due to strong recent financial results, with promising future guidance driving community discussions around significant earnings growth and attractive dividends, supported by favorable technical breakouts and a constructive shipping sector environment.

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

With a February readout of bladder cancer data for TARA-002 and an upcoming ASCO GU presentation creating high community anticipation, Protara Therapeutics is gaining investor attention following recent positive FDA designations and strong analyst sentiment for its oncology and rare disease pipeline.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

Crescent Biopharma (CBIO) is trending following a transformational partnership with Kelun-Biotech and a substantial private placement, which establishes a focused pipeline of next-generation oncology therapeutics for solid tumors. The community is actively discussing the potential of this dual-attack approach and strengthened balance sheet, while also watching for market reaction to the new strategic direction within a competitive biotech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revolution Medicines, Inc. $RVMD Stock Position Decreased by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 90.8% during the 3rd quarter, according to the company in its most recent...

China Universal Asset Management Co. Ltd. Sells 34,644 Shares of Revolution Medicines, Inc. $RVMD

China Universal Asset Management Co. Ltd. decreased its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 44.8% during the third quarter, according to the company in its most...

NEOS Investment Management LLC Acquires 32,694 Shares of Revolution Medicines, Inc. $RVMD

NEOS Investment Management LLC raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 34.7% during the 3rd quarter, according to its most recent filing with the...

Revolution Medicines (RVMD) to Release Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

Revolution Medicines (NASDAQ:RVMD) CEO Mark Goldsmith outlined the company's late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and...

Revolution Medicines, Inc. $RVMD Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH trimmed its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 40.0% during the third quarter, according to its most recent filing with the...

Noteworthy Monday Option Activity: RVMD, BLSH, MDB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Revolution Medicines Inc (Symbol: RVMD), where a total volume of 24,146 contracts...

Stock Traders Purchase High Volume of Put Options on Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 22,906 put options on the company. This is an...

Revolution Medicines, Inc. $RVMD Shares Bought by Candriam S.C.A.

Candriam S.C.A. raised its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 20.7% in the third quarter, according to its most recent Form 13F filing with the Securities...

Revolution Medicines, Inc. $RVMD Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 39.3% during the 3rd quarter, according to the company in its most recent...

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Current Price	$101.83
Prev Close	$102.74
Open	$102.72
Dividend Yield	0.00%
50-Day Moving Average	$95.29
Beta	1.09
Avg. Volume	5.7M
PE Ratio	-19.65

52-Week High	$124.49
52-Week Low	$29.17
Market Capitalization	$19.69B
EPS (Annual)	-$3.58
Price to Book	12.10
Revenue Per Employee	$0.00

RVMD
Revolution Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVMD News

RVMDRevolution Medicines Inc